Intercept study in cirrhotic NASH patients

Brief description of study

The purpose of the study is to find out how safe and effective the investigational drug obeticholic acid (also known as OCA) may be in improving compensated cirrhosis caused by Nonalcoholic steatohepatitis (NASH). This study has two parts. We are recruiting patients with Cirrhosis who meet the inclusion/exclusion criteria for this trial. You will participate in this study for up to 2 years.


Clinical Study Identifier: s17-01084
ClinicalTrials.gov Identifier: NCT03439254
Principal Investigator: James S Park
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.